Thank you!
Your support is sustaining the future of local news in our communities.

Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

After 15 years, Black Rabbit owner says goodbye

Black Rabbit owner Kendra Chapman outside her Lakeville restaurant on Sunday, Nov. 8, its final day after 15 years in business.

Patrick L. Sullivan

LAKEVILLE — After 15 years running the Black Rabbit Bar & Grille, Kendra Chapman decided it was time to stop working 70-hour weeks and spend more time with her family.

The restaurant at 2 Ethan Allen St. closed Sunday, Nov. 8, following a busy final week filled with farewells from longtime customers. She announced the Nov. 8 closing date on Oct. 31.

Keep ReadingShow less
Northwest Corner libraries offer laptops to eligible residents

Sarah Marshall, director of Kent Memorial Library, displays a laptop available through the Laptop ConneCT Library program, now offered at all town libraries in Region One.

Ruth Epstein

NORTHWEST CORNER — Libraries provide much more than books nowadays, and eligible Connecticut residents now have another resource available.

All six libraries in the Region One school district are participating in Laptop ConneCT, a program that allows eligible residents to borrow laptops for long-term use.

Keep ReadingShow less
Kent library honors Sam Callaway as Volunteer of the Year

KENT — Sam Callaway is this year’s recipient of Kent Memorial Library’s Volunteer of the Year Award. The presentation was made by library Director Sarah Marshall at Sunday’s Volunteer Luncheon held at the Community House.

Callaway, an architect, has provided extensive free architectural services over many years for the new library building, which is under construction.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Police Blotter: Troop B

Police Blotter: Troop B
Police Blotter: Troop B
John Coston

The following information was provided by the Connecticut State Police at Troop B. All suspects are considered innocent until proven guilty in a court of law.

North Canaan DUI

Keep ReadingShow less
Sharon median home price reaches $710K, up 16% from a year ago

This home at 88 Sharon Valley Road, set on 6.9 acres with several outbuildings, sold for $675,000.

Christine Bates

SHARON — The median sale price of a single-family home in Sharon reached $710,000 for the 12 months ending Oct. 31.

The median, which excludes condominiums, was 16% higher than the $610,000 recorded for the 12 months ending Oct. 31, 2025, and 5% above the $677,500 recorded for the corresponding period in 2024.

Keep ReadingShow less
Free help navigating Medicare options in Falls Village

Amy Wynn, left, explores Medicare options with Amanda Halle at the David M. Hunt Library Nov. 5.

Patrick L. Sullivan

FALLS VILLAGE — Amanda Halle of the Western Connecticut Area Agency on Aging (WCAAA) was at the David M. Hunt Library Thursday, Nov. 5, to offer assistance with Medicare enrollment.

Halle explained that WCAAA is a nonprofit agency based in Waterbury that offers free assistance for people trying to navigate the intricacies of Medicare.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.